FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183622813> ?p ?o ?g. }

• W3183622813 endingPage "3828" @default.
• W3183622813 startingPage "3828" @default.
• W3183622813 abstract "Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we aimed at refining the selection of patients based on the expression of immune genes. Forty-six consecutive advanced NSCLC patients treated with pembrolizumab in first-line setting were enrolled. The expression levels of 770 genes involved in the regulation of the immune system was analysed by the nanoString system. PD-L1 expression was evaluated by immunohistochemistry. Patients with durable clinical benefit had a greater infiltration of cytotoxic cells, exhausted CD8, B-cells, CD45, T-cells, CD8 T-cells and NK cells. Immune cell scores such as CD8 T-cell and NK cell were good predictors of durable response with an AUC of 0.82. Among the immune cell markers, XCL1/2 showed the better performance in predicting durable benefit to pembrolizumab, with an AUC of 0.85. Additionally, CD8A, CD8B and EOMES showed a high specificity (>0.86) in identifying patients with a good response to treatment. In the same series, PD-L1 expression levels had an AUC of 0.61. The characterization of tumor microenvironment, even with the use of single markers, can improve patients’ selection for pembrolizumab treatment." @default.
• W3183622813 created "2021-08-02" @default.
• W3183622813 creator A5002761212 @default.
• W3183622813 creator A5013482646 @default.
• W3183622813 creator A5017474339 @default.
• W3183622813 creator A5025932455 @default.
• W3183622813 creator A5052697026 @default.
• W3183622813 creator A5062859034 @default.
• W3183622813 creator A5068503607 @default.
• W3183622813 creator A5078125774 @default.
• W3183622813 creator A5079703596 @default.
• W3183622813 creator A5082066847 @default.
• W3183622813 date "2021-07-29" @default.
• W3183622813 modified "2023-10-06" @default.
• W3183622813 title "Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer" @default.
• W3183622813 cites W1976199086 @default.
• W3183622813 cites W1982488143 @default.
• W3183622813 cites W2049553585 @default.
• W3183622813 cites W2103151123 @default.
• W3183622813 cites W2124427232 @default.
• W3183622813 cites W2130030995 @default.
• W3183622813 cites W2341604280 @default.
• W3183622813 cites W2510040899 @default.
• W3183622813 cites W2527905628 @default.
• W3183622813 cites W2655262992 @default.
• W3183622813 cites W2744685612 @default.
• W3183622813 cites W2750328162 @default.
• W3183622813 cites W2753432434 @default.
• W3183622813 cites W2787835497 @default.
• W3183622813 cites W2790164909 @default.
• W3183622813 cites W2791984906 @default.
• W3183622813 cites W2793974615 @default.
• W3183622813 cites W2809138029 @default.
• W3183622813 cites W2897283341 @default.
• W3183622813 cites W2910245285 @default.
• W3183622813 cites W2912137016 @default.
• W3183622813 cites W2912418732 @default.
• W3183622813 cites W2914458127 @default.
• W3183622813 cites W2925446385 @default.
• W3183622813 cites W2952058451 @default.
• W3183622813 cites W2952193508 @default.
• W3183622813 cites W2952406594 @default.
• W3183622813 cites W2954461305 @default.
• W3183622813 cites W2976744492 @default.
• W3183622813 cites W2985170860 @default.
• W3183622813 cites W2991050453 @default.
• W3183622813 cites W2999372945 @default.
• W3183622813 cites W3006011106 @default.
• W3183622813 cites W3008661101 @default.
• W3183622813 cites W3020251873 @default.
• W3183622813 cites W3029668020 @default.
• W3183622813 cites W3031688839 @default.
• W3183622813 cites W3036197269 @default.
• W3183622813 cites W3039206554 @default.
• W3183622813 cites W3092374644 @default.
• W3183622813 cites W3104828024 @default.
• W3183622813 cites W3114042480 @default.
• W3183622813 cites W3119562444 @default.
• W3183622813 cites W3120706113 @default.
• W3183622813 cites W3178186466 @default.
• W3183622813 cites W4241140434 @default.
• W3183622813 cites W4376453325 @default.
• W3183622813 doi "https://doi.org/10.3390/cancers13153828" @default.
• W3183622813 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8345106" @default.
• W3183622813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34359727" @default.
• W3183622813 hasPublicationYear "2021" @default.
• W3183622813 type Work @default.
• W3183622813 sameAs 3183622813 @default.
• W3183622813 citedByCount "6" @default.
• W3183622813 countsByYear W31836228132022 @default.
• W3183622813 countsByYear W31836228132023 @default.
• W3183622813 crossrefType "journal-article" @default.
• W3183622813 hasAuthorship W3183622813A5002761212 @default.
• W3183622813 hasAuthorship W3183622813A5013482646 @default.
• W3183622813 hasAuthorship W3183622813A5017474339 @default.
• W3183622813 hasAuthorship W3183622813A5025932455 @default.
• W3183622813 hasAuthorship W3183622813A5052697026 @default.
• W3183622813 hasAuthorship W3183622813A5062859034 @default.
• W3183622813 hasAuthorship W3183622813A5068503607 @default.
• W3183622813 hasAuthorship W3183622813A5078125774 @default.
• W3183622813 hasAuthorship W3183622813A5079703596 @default.
• W3183622813 hasAuthorship W3183622813A5082066847 @default.
• W3183622813 hasBestOaLocation W31836228131 @default.
• W3183622813 hasConcept C126322002 @default.
• W3183622813 hasConcept C143998085 @default.
• W3183622813 hasConcept C154317977 @default.
• W3183622813 hasConcept C167672396 @default.
• W3183622813 hasConcept C202751555 @default.
• W3183622813 hasConcept C203014093 @default.
• W3183622813 hasConcept C2776107976 @default.
• W3183622813 hasConcept C2776256026 @default.
• W3183622813 hasConcept C2777701055 @default.
• W3183622813 hasConcept C2780057760 @default.
• W3183622813 hasConcept C2781053074 @default.
• W3183622813 hasConcept C502942594 @default.
• W3183622813 hasConcept C55493867 @default.
• W3183622813 hasConcept C71924100 @default.
• W3183622813 hasConcept C86803240 @default.

• next